Alimera Sciences (Alimera Sciences) Interest Expense : $-10.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alimera Sciences's interest expense for the three months ended in Dec. 2023 was $ -4.75 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alimera Sciences's Operating Income for the three months ended in Dec. 2023 was $ 0.72 Mil. Alimera Sciences's Interest Expense for the three months ended in Dec. 2023 was $ -4.75 Mil. Alimera Sciences's Interest Coverage for the quarter that ended in Dec. 2023 was 0.15. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alimera Sciences Interest Expense Historical Data

The historical data trend for Alimera Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Interest Expense Chart

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.87

-5.38

-5.41

-5.88

-10.19

Alimera Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.63	-1.67	-1.69	-2.07	-4.75

Alimera Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.19 Mil.

Alimera Sciences (NAS:ALIM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alimera Sciences's Interest Expense for the three months ended in Dec. 2023 was $-4.75 Mil. Its Operating Income for the three months ended in Dec. 2023 was $0.72 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $64.49 Mil.

Alimera Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	0.724	/	-4.754
	=	0.15

The higher the ratio, the stronger the company's financial strength is.

Alimera Sciences (Alimera Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Executives

Margaret Pax	director	6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko	director	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp	10 percent owner	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont	director	51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers	other: Chairman Emeritus	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan	director	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc	10 percent owner	1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman	10 percent owner	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076